pharmaphorum
SEPTEMBER 17, 2020
Patient simulations have been a key tool for educating physicians for decades – and now cutting-edge tech is helping them become more impactful than ever. • Read the latest issue Deep Dive: Communications 2020 in full. The post Deep Dive: Communications 2020 appeared first on. Subscribe to future issues of Deep Dive.
pharmaphorum
NOVEMBER 2, 2020
Ahead of Frontiers Health 2020, steering committee members Roberto Ascione and Paul Tunnah from Healthware give us their thoughts on the trends driving the bright future of digital health. The post Deep Dive: Digital Health Innovation 2020 appeared first on. The key elements driving the success of digital health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
JULY 19, 2023
But in order to be truly effective, sponsorships must be aligned with a company’s brand values. For pharmaceutical companies, this means aligning sponsorships with causes that are related to health and wellness. In 2020, the company committed to investing $5 billion in research and development over the next five years.
STAT
NOVEMBER 15, 2023
The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10.
European Pharmaceutical Review
APRIL 8, 2024
A study investigating the trend for existing pharmaceutical companies to outsource to contracted development and manufacturing organisations (CDMOs), analysing the position of companies manufacturing monoclonal antibody drugs (mAbs). Yoshiura et al. Yoshiura et al. Yoshiura et al. Yoshiura et al.
STAT
MAY 11, 2023
Thanks to changes in tax law six years ago, several of the largest pharmaceutical companies saw their tax rates fall substantially, but they also reported that most of their profits were shifted offshore in an effort to avoid paying U.S. in 2020, down from 19.6% in 2020, down from 19.6% Senate Committee.
Hospital Pharmacy Europe
MARCH 7, 2024
Many oncology drugs approved by the European Medicines Agency (EMA) between 2005 and 2020 provide ‘little or no added benefit’ for patients, according to new research. Many drugs with higher benefit ratings were associated with more significant revenues for the associated pharmaceutical companies, they added.
Expert insights. Personalized for you.
52 
Let's personalize your content